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Background
Tuberculosis (TB) causes significant morbidity and mor-
tality globally. High efficacy in clinical trials of the current
4-drug 6-month regimen does not always translate into
practice due to a heavy pill burden and long duration.
New drugs are in late-phase clinical development, so trials
that evaluate novel and existing drugs in combination are
urgently needed. A multi-arm multi-stage (MAMS) design,
with planned interim analyses allowing stopping of arms
not showing benefit, has been developed and used in
oncology. We have adapted this approach to create the
PanACEA MAMS-TB 5-arm 3-stage phase II trial evaluat-
ing new treatments for TB.
Methods
The transition from an endpoint of progression-free survi-
val to one of negative culture conversion required several
modifications including allowing for fixed follow-up of
12 weeks and targeting an increase in the hazard of the
event rather than a decrease. The Weibull distribution was
used in place of the exponential distribution to model a
more appropriate increasing hazard. The option of a sec-
ond interim analysis protects against slow recruitment.
Results
In this paper, the modifications to the design will be
explained with discussion around pair-wise and family-
wise type I error rates, power and expected sample size
in comparison with a fixed sample design.
Conclusions
Reductions in expected sample size are moderate in this
relatively small 5-arm study due to the absence of a real-
time biomarker. Nevertheless, there is potential for faster
evaluation of more regimens in a larger phase II/III
design once better biomarkers are validated.
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